Kim D.  Janda net worth and biography

Kim Janda Biography and Net Worth

Dr. Janda has served as a director since April 2012. Dr. Janda has been the Ely R. Callaway, Jr. Chaired Professor in the Departments of Chemistry, Immunology and Microbial Science at The Scripps Research Institute (“TSRI”) since 1996 and as the Director of the Worm Institute of Research and Medicine (“WIRM”) at TSRI since 2005. Furthermore, Dr. Janda has served as a Skaggs Scholar within the Skaggs Institute of Chemical Biology, also at TSRI, since 1996.

Dr. Janda has published more than 425 original publications in peer-reviewed journals and founded the biotechnological companies CombiChem, Drug Abuse Sciences and AIPartia. Dr. Janda is an associate editor of “Bioorganic & Medicinal Chemistry”, “PLoS ONE” and serves, or has served, on editorial boards of numerous journals including J. Comb. Chem., Chem. Reviews, J. Med. Chem., The Botulinum Journal, Bioorg. & Med. Chem. Lett., and Bioorg. & Med. Chem.

Over a career of more than 25 years, Dr. Janda has provided numerous seminal contributions and is considered one of the first scientists to merge chemical and biological approaches into a cohesive research program. Dr. Janda has served on the Scientific Advisory Boards of Materia and Singapore Ministry of Education.

Dr. Janda holds a B.S. degree from the University of South Florida in Clinical Chemistry and his Ph.D. from the University of Arizona with Robert B. Bates in Natural Product Total Synthesis.

What is Kim D. Janda's net worth?

The estimated net worth of Kim D. Janda is at least $73.50 as of April 12th, 2021. Dr. Janda owns 4,900 shares of Sorrento Therapeutics stock worth more than $74 as of April 23rd. This net worth approximation does not reflect any other investments that Dr. Janda may own. Learn More about Kim D. Janda's net worth.

How do I contact Kim D. Janda?

The corporate mailing address for Dr. Janda and other Sorrento Therapeutics executives is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. Sorrento Therapeutics can also be reached via phone at (858) 203-4100 and via email at [email protected]. Learn More on Kim D. Janda's contact information.

Has Kim D. Janda been buying or selling shares of Sorrento Therapeutics?

Kim D. Janda has not been actively trading shares of Sorrento Therapeutics within the last three months. Most recently, Kim Janda sold 3,000 shares of the business's stock in a transaction on Monday, December 27th. The shares were sold at an average price of $5.88, for a transaction totalling $17,640.00. Learn More on Kim D. Janda's trading history.

Kim D. Janda Insider Trading History at Sorrento Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/27/2021Sell3,000$5.88$17,640.00View SEC Filing Icon  
9/27/2021Sell42,357$8.02$339,703.14View SEC Filing Icon  
9/13/2021Sell8,000$8.04$64,320.00View SEC Filing Icon  
4/12/2021Sell1,900$6.97$13,243.004,900View SEC Filing Icon  
See Full Table

Kim D. Janda Buying and Selling Activity at Sorrento Therapeutics

This chart shows Kim Janda's buying and selling at Sorrento Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sorrento Therapeutics Company Overview

Sorrento Therapeutics logo
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $0.02
Low: $0.01
High: $0.02

50 Day Range

MA: $0.02
Low: $0.01
High: $0.05

2 Week Range

Now: $0.02
Low: $0.00
High: $0.42

Volume

136,932 shs

Average Volume

503,964 shs

Market Capitalization

$8.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.25